“Medicine for All the Right Reasons”: Improving U.S. Veterans’ Enrollment in Cancer Clinic TrialsA pilot initiative aims to expand access and increase veteran enrollment in clinical trials through a tailored approach designed to boost awareness and options. Nov 05 26November 05, 2026Article at ASCO Connection
Private Sector Efforts Are Helping Community Oncology Practices Offer Clinical TrialsExplore how private sector initiatives are supporting community oncology practices in offering clinical trials, addressing barriers to access and improving patient outcomes. Nov 04 26November 04, 2026Article at OBR
Losing NCOA6 Linked to Aggressive Prostate Cancer With EGFR OverexpressionDiscover how NCOA6 loss is associated with aggressive prostate cancer and EGFR overexpression, highlighting potential therapeutic targets. Nov 04 26November 04, 2026Article at OBR
Community Oncology Looks to Outcomes Data to Demonstrate QualityCommunity oncology practices can point to advantages such as care closer to home, greater affordability, and a more personalized experience. However, demonstrating the quality of that care with data can be more challenging. Sep 28 26September 28, 2026Article at OBR
How Community Oncology Practices Are Making Bundled Payments WorkLearn how community oncology practices are successfully implementing bundled payments, improving care coordination, and reducing costs for cancer patients. Sep 28 26September 28, 2026Article at OBR
Oncology Partnerships Offer New Approach to Utilization ManagementExplore how oncology partnerships are transforming utilization management through innovative approaches that improve patient care and streamline processes. Sep 24 26September 24, 2026Article at OBR
What Do Phase 3 mRNA Vaccine Results Mean for Melanoma?Explore the phase 3 mRNA vaccine results and their implications for melanoma treatment and prevention. Sep 22 26September 22, 2026Article at OBR
“Missed Opportunity”: Real-World Outcomes Underscore Importance of Genomic Testing in Prostate CancerStudy finds HRR mutations in metastatic prostate cancer may lead to worse overall survival and progression-free survival. Aug 31 26August 31, 2026Article at OBR
Daraxonrasib Gains FDA Approval for Pancreatic CancerDaraxorasib (Rasonque) is approved for metastatic pancreatic ductal adenocarcinoma, offering new treatment options for patients. Aug 26 26August 26, 2026Article at OBR
FDA Approves Bispecific Combinations for HER2+ Gastroesophageal CancersFDA approves zanidatamab for HER2-positive gastroesophageal cancer in frontline settings, offering a new treatment option for patients. Aug 26 26August 26, 2026Article at OBR
FDA Approves Combo Regimen for Metastatic Hormone-Sensitive Prostate CancerFDA approves lutetium Lu 177 vipivotide tetraxetan plus ARPI for metastatic hormone-sensitive prostate cancer, expanding treatment options. Aug 03 26August 03, 2026Article at OBR
Talazoparib and Enzalutamide Combo Shows Promise in Treating Certain Prostate CancersLearn how talazoparib and enzalutamide improve progression-free survival in men with metastatic castration-sensitive prostate cancer. Aug 03 26August 03, 2026Article at OBR
Twice-Rejected Advanced Melanoma Treatment Wins FDA Committee VoteFDA panel recommends approval for Vusolimogene oderparepvec to treat advanced melanoma, marking a significant advancement in cancer therapy. Jul 31 26July 31, 2026Article at OBR
Fallout From Headline-Grabbing Cancer Study’s Retraction: Does Time of Day Matter for Treatment?The LungTIME-C01 study linking immunochemotherapy timing to survival in lung cancer was retracted. Learn what this means for treatment scheduling. Jul 30 26July 30, 2026Article at OBR
ASCO Issues First Guideline for ctDNA Testing in Solid Tumors, LymphomaThe American Society of Clinical Oncology issued its first guidelines for the use of blood-based ctDNA testing in diagnosis, therapy selection, surveillance, and prognosis in solid tumors and lymphoma. Among the key recommendations is that ctDNA should be used as a complementary tool versus a replacement for standard testing. Jul 24 26July 24, 2026Article at OBR
AYA Patients With Sarcoma Face Gaps in Treatment, Palliative CareAYA cancer patients with sarcoma may not know resources, including palliative care, are available, and may resist them when offered. Jul 22 26July 22, 2026Article at Cancer Therapy Advisor
Candidiasis Remains Persistent in the ICU, Analysis FindsAn analysis of more than 200 hospitals found a very high mortality rate in non–COVID-19 ICU patients with invasive candidiasis. Jul 16 26July 16, 2026Article at Infectious Disease Special Edition
Tofacitinib Shows Potential as a Second-Line Option for Severe, Steroid-Refractory Immune-Related Adverse EventsIn a single-arm, 2-stage study, tofacitinib reduced irAE rates, suggesting its potential as a bridging therapy to resolve irAEs and enable resumption of ICI treatment (Abstract 81). Randomized clinical trials involving multiple study centers and comparisons with standard glucocorticoid therapy are needed to further explore tofacitinib for addressing irAEs. Jul 01 26July 01, 2026Article at ASCO Daily News
New Therapies, Testing Drive Advances in Early-Stage Breast CancerThe latest findings from ASCO 2026 show how new treatment paradigms are shifting in early-stage breast cancer. Jun 12 26June 12, 2026Article at Cancer Therapy Advisor
Could Trial Herald “Seismic Shift” in Certain Early-Stage NSCLC?Adjuvant selpercatinib improves event-free survival in early-stage RET-positive NSCLC, potentially changing post-surgery treatment. Jun 03 26June 03, 2026Article at OBR